BACKGROUND: Calprotectin is a marker associated with intestinal inflammation. The aim of this study is to explore the diagnostic value of fecal calprotectin in predicting bacterial/viral diarrhea and the application of fecal calprotectin in the clinical course of infectious diarrhea. METHODS: Patients ages from 3 months to 10 years with infectious diarrhea were enrolled, and from each patient, 2 to 3 stool samples were collected. Fecal calprotectin levels were determined by enzyme-linked immunosorbent assay and compared by pathogen and disease activity. A univariate linear regression was used to determine the correlation between fecal calprotectin and the clinical parameters, and generalized estimating equations (GEEs) were used for the time course analyses. RESULTS: The data include 451 evaluations for 153 individuals across 3 different time points. The fecal calprotectin level was higher in patients with Salmonella infection (median with range 765 [252-1246] μg/g) or Campylobacter infection (689 [307-1046] μg/g) compared with patients with rotavirus infection (89 [11-426] μg/g), norovirus infection (93 [25-405] μg/g), or adenovirus infection (95 [65-224] μg/g). Fecal calprotectin concentrations were elevated in patients with severe (843 [284-1246] μg/g) or moderate (402 [71-995] μg/g) disease activity compared with those with mild (87 [11-438] μg/g) disease activity (P < 0.05). GEE analysis suggests that fecal calprotectin is correlated with clinical severity (e.g., Vesikari score) and may provide information for disease management. CONCLUSIONS: Fecal calprotectin levels increased during bacterial infection and as disease severity increased, and its levels on the initial evaluation and follow-up visit are correlated with clinical severity. Fecal calprotectin may be a useful marker for application in children during infectious diarrhea.
BACKGROUND: Calprotectin is a marker associated with intestinal inflammation. The aim of this study is to explore the diagnostic value of fecal calprotectin in predicting bacterial/viral diarrhea and the application of fecal calprotectin in the clinical course of infectious diarrhea. METHODS:Patients ages from 3 months to 10 years with infectious diarrhea were enrolled, and from each patient, 2 to 3 stool samples were collected. Fecal calprotectin levels were determined by enzyme-linked immunosorbent assay and compared by pathogen and disease activity. A univariate linear regression was used to determine the correlation between fecal calprotectin and the clinical parameters, and generalized estimating equations (GEEs) were used for the time course analyses. RESULTS: The data include 451 evaluations for 153 individuals across 3 different time points. The fecal calprotectin level was higher in patients with Salmonella infection (median with range 765 [252-1246] μg/g) or Campylobacter infection (689 [307-1046] μg/g) compared with patients with rotavirus infection (89 [11-426] μg/g), norovirus infection (93 [25-405] μg/g), or adenovirus infection (95 [65-224] μg/g). Fecal calprotectin concentrations were elevated in patients with severe (843 [284-1246] μg/g) or moderate (402 [71-995] μg/g) disease activity compared with those with mild (87 [11-438] μg/g) disease activity (P < 0.05). GEE analysis suggests that fecal calprotectin is correlated with clinical severity (e.g., Vesikari score) and may provide information for disease management. CONCLUSIONS: Fecal calprotectin levels increased during bacterial infection and as disease severity increased, and its levels on the initial evaluation and follow-up visit are correlated with clinical severity. Fecal calprotectin may be a useful marker for application in children during infectious diarrhea.
Authors: Gea A Holtman; Yvonne Lisman-van Leeuwen; Boudewijn J Kollen; Obbe F Norbruis; Johanna C Escher; Angelika Kindermann; Yolanda B de Rijke; Patrick F van Rheenen; Marjolein Y Berger Journal: Ann Fam Med Date: 2016-09 Impact factor: 5.166
Authors: Ashwini Banerjee; M Srinivas; Richard Eyre; Robert Ellis; Norman Waugh; K D Bardhan; P Basumani Journal: Frontline Gastroenterol Date: 2014-04-02
Authors: Eliza Lężyk-Ciemniak; Magdalena Tworkiewicz; Dominika Wilczyńska; Anna Szaflarska-Popławska; Aneta Krogulska Journal: Med Princ Pract Date: 2020-10-29 Impact factor: 1.927
Authors: Sue E Crawford; Sasirekha Ramani; Jacqueline E Tate; Umesh D Parashar; Lennart Svensson; Marie Hagbom; Manuel A Franco; Harry B Greenberg; Miguel O'Ryan; Gagandeep Kang; Ulrich Desselberger; Mary K Estes Journal: Nat Rev Dis Primers Date: 2017-11-09 Impact factor: 52.329
Authors: Andi L Shane; Rajal K Mody; John A Crump; Phillip I Tarr; Theodore S Steiner; Karen Kotloff; Joanne M Langley; Christine Wanke; Cirle Alcantara Warren; Allen C Cheng; Joseph Cantey; Larry K Pickering Journal: Clin Infect Dis Date: 2017-11-29 Impact factor: 9.079
Authors: Vladimir E Diaz-Ochoa; Diana Lam; Carlin S Lee; Suzi Klaus; Judith Behnsen; Janet Z Liu; Nicholas Chim; Sean-Paul Nuccio; Subodh G Rathi; Jennifer R Mastroianni; Robert A Edwards; Christina M Jacobo; Mauro Cerasi; Andrea Battistoni; André J Ouellette; Celia W Goulding; Walter J Chazin; Eric P Skaar; Manuela Raffatellu Journal: Cell Host Microbe Date: 2016-06-08 Impact factor: 21.023